Targeted high-dose radiation added to standard lung cancer treatment
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that can’t be removed by surgery (stage IIB or III) and it has spread to lymph nodes
- Your lung cancer diagnosis is confirmed by lab testing (biopsy/sputum/cytology), and your tumor size is 7 cm or smaller
- Your scans show no spread to distant organs (no distant metastases) within 60 days of starting the study
- You can have the needed pre-treatment tests, including brain MRI (preferred) or CT, and a CT chest with contrast
- You are at least 18 years old, can do usual activities with some limits (ECOG 0–2), and your blood/organ tests are adequate for chemo and radiation
- You cannot have had radiation to the same lung cancer area before, and you must have an identifiable primary tumor (not T3–4N0 or T0N1–3)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies adding focused radiation to some cancer spots in people with stage III non-small cell lung cancer (NSCLC) whose cancer did not fully stop after standard chemoradiation and durvalumab. The goal is to control a small number of growing spots (or more than a few) and improve outcomes after durvalumab.
This trial tests whether adding a high, focused dose of radiation to the usual first treatment (chemo and/or immunotherapy) can help people with non-small cell lung cancer that has spread to a limited number of spots (up to 5). The goal is to see if this approach improves how well the treatment works.
This trial tests a new way of giving radiation (in high and low doses) together with chemotherapy and immunotherapy to treat advanced non-small cell lung cancer. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a personalized (“adaptive”) radiation plan combined with pembrolizumab, and possibly chemotherapy, for advanced stage IV lung cancer. It aims to improve cancer control while carefully managing side effects, including in patients with certain brain metastases.
This trial tests giving radiation and immunotherapy together to people with advanced lung cancer that hasn't been treated yet. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new combination of chemotherapy, radiation, and immunotherapy (durvalumab) for people with stage III non-small cell lung cancer that cannot be removed with surgery. The goal is to see if giving a smaller, more focused radiation dose can be just as effective with fewer side effects.
Hear when a new Locally Advanced Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.